News

Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...
Lilly requests EMA to re-examine Alzheimer's drug recommendation
Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...
Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs
Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
Modern Healthcare2d
Eli Lilly sues four telehealth compounding GLP-1 companies
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss ...
Pharmaceutical Technology on MSN2d
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...